This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Immunomedics Announces Clivatuzumab-Based Blood Test Can Differentiate Between Pancreatic Cancer And Chronic Pancreatitis

Stock quotes in this article: IMMU

WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company's humanized antibody, clivatuzumab, is specifically reactive with pancreatic ductal adenocarcinoma (PDAC) and does not react with chronic pancreatitis (CP) tissues. Dr. David V. Gold, Director of Laboratory Administration and Senior Member of the Garden State Cancer Center in Morris Plains, NJ, presented the study at the 2013 Annual Meeting of the American Association for Cancer Research in Washington, DC.

"These data have strong implications for the clivatuzumab-based blood test, suggesting that individuals diagnosed with CP who are found to be positive for this blood test, may in fact have cancer, and should be followed closely for further indications of PDAC," commented Dr. Gold. The clivatuzumab-based blood test has previously been shown to correctly identify nearly two thirds of patients with early stage pancreatic cancer. (For more information, please refer to the Company press release at www.immunomedics.com/pdfs/news/2012/pr01182012.pdf ).

According to the American Cancer Society, pancreatic cancer is the 10 th most common cancer diagnosis among men and the 9 th most common among women in the U.S. In 2013, an estimated 45,220 new cases will be diagnosed nationwide. The malignancy is one of the deadliest cancer types, accounting for about 7% of all cancer deaths and is the fourth leading cause of cancer death among both men and women. In 2013, approximately 38,460 people are expected to die from pancreatic cancer nationwide.

The prognosis of pancreatic cancer is largely determined by the stage of the disease at diagnosis, with median survival ranges from 4.5 months for the most advanced stage to 24.1 months for the earliest stage. However, only about 7% of pancreatic cancer cases are diagnosed at the early stages. It is, therefore, generally recognized that better tests to diagnose pancreatic cancer earlier, before it has metastasized, are needed.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,916.32 -126.58 -0.74%
S&P 500 1,959.28 -13.01 -0.66%
NASDAQ 4,448.1740 -45.2160 -1.01%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs